
Tirzepatide
Tirzepatide (LY3298176)
Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide built on the native GIP sequence and engineered to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It contains two Aib residues for protease resistance and a lysine at position 20 acylated with a C20 fatty diacid through a γGlu-AEEA-AEEA linker, giving it an extended half-life through albumin binding.
Its discovery and preclinical pharmacology were described by Coskun and colleagues in Molecular Metabolism in 2018. Because it is "imbalanced", with GIP receptor potency comparable to native GIP and weaker potency at the GLP-1 receptor, it is a key reference compound for studying how dual incretin signaling differs from selective GLP-1 agonism.
Tirzepatide is the active ingredient in FDA-approved prescription drugs; this product is a research-grade material, not a drug product. PhysIQ Peptides supplies it as a lyophilized powder, third-party tested for purity and identity, for in vitro and laboratory research use only.
Select size
Choose how to buy
You save $6.75 every reship · ≈ $82.13 saved per year
Auto-delivered • Skip or cancel anytime • Never run out
Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.
- Purity
- 99%
- Form
- Powder (lyophilized)
- CAS Number
- 2023788-19-2
- Molecular Formula
- C225H348N48O68
- Molecular Weight
- 4813.45 g/mol
- Available sizes
- 20mg, 40mg
Sequence
Y-Aib-EGTFTSDYSI-Aib-LDKIAQK(γGlu-2xAEEA-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2
Mechanism of Action
Tirzepatide binds and activates both GIPR and GLP-1R. In cell-based assays its affinity at the GIP receptor is similar to native GIP, while at the GLP-1 receptor it is several-fold weaker than native GLP-1 and shows biased signaling, favoring cAMP generation over β-arrestin recruitment. Researchers use it to study how combined incretin receptor activation affects insulin secretion and receptor internalization compared with single-receptor agonists.
Research Areas
- ●Dual incretin receptor pharmacology (GIPR / GLP-1R)
- ●Biased agonism and β-arrestin signaling
- ●Beta-cell and insulin secretion models
- ●Peptide acylation and half-life engineering
Selected References
- Coskun T, et al. Mol Metab. 2018;18:3-14.




